Day: February 22, 2025

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological-endoscopic mucosal improvement Findings to form the basis for a phase 3 program, anticipated to start in H2 2025 Paris and Parsippany, NJ, February 22, 2025. Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 monoclonal antibody targeting TL1A, in patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD), the two most common...

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ETNew detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025PARSIPPANY, N.J. and PARIS, Feb. 22, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi today presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for the treatment of moderate-to-severe ulcerative colitis (UC) and Crohn’s...

HOUSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) — Today, Sysco Corporation, the leading global foodservice distribution company, recalled frozen supplemental shakes linked to a Listeria monocytogenes outbreak and halted all purchases of other products supplied by Lyons Magnus from a Fort Wayne, Ind., facility. Lyons Magnus supplied Sysco Imperial and Lyons ReadyCare supplemental shakes linked to the outbreak. Sysco is immediately removing all the recalled items from its inventory, notifying potentially implicated downstream customers of the recall, and halting production of all products that originate from that facility. Additional actions will be taken as needed, and Sysco will continue to cooperate with all agencies. Sysco expresses our most sincere condolences with those affected by this outbreak and their families. Food safety is and...

– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES – Vancouver, British Columbia, Feb. 22, 2025 (GLOBE NEWSWIRE) — American Tungsten Corp. (CSE:TUNG) (OTCQB: DEMRF) (FSE: RK9) (the “Company” or “American Tungsten“) is pleased to announce that due to significant market demand, the Company has increased the size of its previously announced non-brokered private placement under the Listed Issuer Financing Exemption (as defined herein) from $2,000,000 to up to $2,500,000. The upsized offering (the “LIFE Offering”) will consist of up to 1,562,500 common shares in the capital of the Company (the “Offered Shares”) at a price of $1.60 per Offered Share for gross proceed of up to $2,500,000. Subject to compliance with applicable regulatory requirements and in accordance with...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Feb. 21, 2025 (GLOBE NEWSWIRE) — Hampton Financial Corporation (“Hampton” or the “Company”, TSXV: HFC) announces that Hampton debentures in the aggregate principal amount of $2,175,000 have been redeemed and that the holders of the debentures have reinvested the redemption proceeds into new non-convertible debentures of Hampton in the aggregate principal amount of $2,000,000, bearing interest at 10% per annum and maturing on December 29, 2025, and separately in the case of debentures held by its CEO, Peter Deeb, in the issuance of 255,050 subordinate voting shares of Hampton at $0.70 per share. The Company received conditional approval from the TSX Venture Exchange for the issuance of the subordinate voting shares, which are subject...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 21, 2025 (GLOBE NEWSWIRE) — Integral Metals Corp. (CSE: INTG | FSE: ZK9) (the “Company” or “Integral”) is pleased to announce that it intends to complete a non-brokered private placement offering (the “Private Placement”) of common shares of the Company (the “Common Shares”) at a price of US$0.70 per Common Share, for gross proceeds of up to US$2,000,000. The Company intends to use the net proceeds of the Private Placement for expenditures on mineral exploration properties, and for general working capital purposes. All securities issued under the Private Placement will be subject to a four-month and one-day hold period. Closing of the Private Placement will be subject to certain customary conditions, including...

BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) — The New America High Income Fund, Inc. (the “Fund”) (NYSE: HYB) announced today that the reorganization of the Fund into the T. Rowe Price High Yield Fund (the “T. Rowe Price Fund”), a separate series of the T. Rowe Price High Yield Fund, Inc. (the “Reorganization”), initially expected to close following the close of business of the New York Stock Exchange on Friday, February 21, 2025, is now expected to close on a mutually agreed upon date in writing by the parties, subject to satisfaction of customary closing conditions. Upon the closing of the Reorganization, shareholders of the Fund will become holders of Investor Class shares of the T. Rowe Price Fund. About the FundThe New America High Income Fund, Inc. is a diversified, closed-end management investment company with a leveraged capital...